Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-03-26
2003-04-08
Wang, Andrew (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S325000, C435S375000, C536S023100, C536S024500
Reexamination Certificate
active
06544958
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to novel nucleotides, and more specifically, ribonucleotide oligonucleotides (RNOs) that are specifically designed to inhibit viral replication at the intracellular sites of infection in the respiratory tract. The RNOs are capable of binding to both the negative and positive strands of influenza RNA segments, thereby inhibiting the virus' ability to produce various viral components, and therefore inhibit viral propagation. The RNOs provided may be formulated in liposomes, which facilitate their therapeutic delivery to intracellular sites of infection, and additionally increase antiviral efficacies.
BACKGROUND OF THE INVENTION
Despite recent advances in antiviral therapy and vaccination; acute respiratory infections caused by influenza viruses are important causes of human mortality and morbidity worldwide. Although influenza viruses generally cause a mild malaise in healthy individuals, for the high-risk segments of the population, such as the elderly, the young, and individuals with underlying chronic illness, influenza and the complications resulting from secondary infections, can be life threatening. It is estimated that in the United States alone, more than 10,000 people die each year from influenza and complications from influenza.
DESCRIPTION OF THE RELATED ART
Vaccination, or immunoprophylaxis, using inactivated or killed whole virus is a widely used conventional preventative measure used to reduce the impact of influenza [Centers for Disease Control,
Prevention and control of influenza: recommendations of the Immunization Practices Advisory Committee Weekly Report,
1991; 41 (RR-9) 1-5]. However, there are significant limitations and drawbacks in such an antiviral vaccination.
A major disadvantage with killed whole virus, or inactivated, influenza virus vaccinations is that they are ineffective against new virus variants that result from genetic changes, such as those changes that arise from antigenic shifts in the haemagglutinin (HA) protein resulting in variations from one HA subtype to another. In addition, because such virus vaccines are propagated in eggs, individuals or populations that are sensitive to eggs and egg products are unsuitable for such vaccination.
Another conventional preventative measure used to reduce or control the impact of influenza is chemoprophylaxis, or chemotherapy, with an influenza-specific antiviral drug, such as amantadine or rimantadine [Centers for Disease Control.
Prevention and control of influenza: recommendations of the Immunization Practices Advisory Committee Weekly Report,
1991; 41 (RR-9) 1-5]. In addition, neuraminidase inhibitors have also been recently commercialized for the treatment of influenza.
There are however, limitations to the use of such anti-influenza drugs. In particular, anti-influenza drugs such as amantadine and rimantadine are only partially effective against influenza A viruses, and are essentially ineffective against B strains of the influenza virus. Moreover, there is a rapidly increasing number of influenza A viruses that are developing resistance to amantadine and rimantadine, whereby such antiviral drugs are becoming rapidly ineffective against these more resistant strains of influenza A virus [Bleshe, R. B., et al, (1989),
J. Infect. Dis.,
159: 430-435].
Oligonucleotides are promising therapeutic agents that have been shown to be effective against cancer and infectious diseases. The prior art also includes the use of antisense deoxyribonucleotides to treat neoplastic and infectious diseases [Mizuta, T., et al, (1999)
Nature Biotechnology,
17 (6), 583-587]. Oligonucleotides directed against a target gene or messenger RNA can result in the inhibition of transcription and/or translation of virus genetic material, thereby blocking the synthesis of key virus proteins required for virus propagation. However, such unmodified oligonucleotides are particularly susceptible to degradation by nucleases in the serum, thus limiting their therapeutic potential.
Liposomes are microscopic lipid vesicles and they have been used successfully as drug delivery systems to enhance the therapeutic effectiveness of a number of therapeutic agents against influenza infections, including antiviral antibodies [Wong, J. P., et al, (1994)
Immunology,
81:280-284], interferon-gamma [Saravolac, E. G., et al, (1996)
Antiviral Res.,
29:199-207] and ribavirin [Kende, M., et al, (1985)
Antimirob. Agents Chemotherapy.,
27:903-907].
It is known to use antisense deoxyribonucleotide oligonucleotides (i.e. DNA molecules) to treat viral infections. In addition, the known antisense oligonucleotides are adversely restricted to gene targets.
The present invention seeks to overcome the obstacles encountered in the prior art and provides the use of novel ribonucleotides, and liposome encapsulated ribonucleotides for the treatment of viral infection, and in particular influenza virus infection. The use of liposomes in this invention allows not only for the oligonucleotides be protected by nuclease degradation, but also allows the oligonucleotides to be delivered to the intracellular sites of infection in the lungs, thereby resulting in enhancing their antiviral inhibition efficacy.
Thus, an object of the present invention is to provide ribonucleotide oligonucleotides (RNOs), either free, or encapsulated in liposomes for the prevention and treatment of viral infections. The use of RNOs offers several distinct advantages over antisense deoxyribonucleotides oligonucleotides. For example, influenza virus, which is an RNA virus, replicates itself by transcribing its RNA into mRNA and then proceeds to translate mRNA into viral proteins. Subsequent to such protein synthesis, the replication of the viral RNA takes place via a synthesis of the cRNA. Accordingly, the use of RNOs, provided according to the present invention, will allow for the binding of such RNOs to either the viral RNA, cRNA and/or mRNA, therefore allowing for the increased functional efficacy in the treatment and prevention of viral infection.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a method for treating, preventing and/or controlling influenza virus infections.
A particular object of the present invention is to provide novel ribonucleotides (RNOs) sequences specifically designed to inhibit viral replication and proliferation at intracellular sites of infection.
Another object of the present invention is to provide novel RNOs specifically designed to inhibit influenza virus replication and proliferation at intracellular sites of infection.
The present invention provides a plurality of ribonucleotide oligonucleotides (RNOs) with specific sequences, which act individually or collectively as therapeutic agents in the treatment and prevention of viral infection, and more specifically, influenza viral infection.
Accordingly, one aspect of the present invention provides a ribonucleotide having the following sequence:
ribonucleotide JW-T1 represented by oligonucleotide sequence SEQ ID NO: 1;
ribonucleotide JW-T2 represented by oligonucleotide sequence SEQ ID NO: 2;
ribonucleotide JW-T3 represented by oligonucleotide sequence SEQ ID NO: 3;
Reference will also be made to the following negative control sequence:
ribonucleotide JW-T4 represented by oligonucleotide sequence SEQ ID NO: 4;
wherein RNO JW-T4 does not inhibit the virus, and is provided for use in control studies relating to the present invention.
In addition, the present invention provides a ribonucleotide sequence including any one of RNOs JW-T1, JW-T2, or JW-T3, or any equivalent sequence thereof, or any combination thereof. Therefore, the present invention is not limited by RNOs sequences JW-T1, JW-T2, or JW-T3 represented in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, but embodies any equivalent sequences, and larger fragment sequences, that may be used in accordance with the preferred uses of the present invention.
A preferred embodiment of the pre
Nagata Leslie P.
Wong Jonathan P. H.
Her Majesty the Queen in right of Canada as represented by the
Nixon & Vanderhye P.C.
Schultz James D.
Wang Andrew
LandOfFree
Therapy of respiratory influenza virus infection using free... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapy of respiratory influenza virus infection using free..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy of respiratory influenza virus infection using free... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3053541